High‐Density Lipoprotein‐Associated Cholesterol Abnormalities in a Clinical Outcomes Study of Dysferlin‐Deficient Limb–Girdle Muscular Dystrophy Type R2

• Published in: Journal of cachexia, sarcopenia and muscle Vol. 16; no. 4; pp. e70042 - n/a
• Main Authors: White, Zoe, Rufibach, Laura, Dressman, Heather Gordish, Hilsden, Heather, Cox, Dan, Spuler, Simone, Day, John W., Jones, Kristi J., Bharucha‐Goebel, Diana X., Salort‐Campana, Emmanuelle, Pestronk, Alan, Walter, Maggie C., Paradas, Carmen, Stojkovic, Tanya, Mori‐Yoshimura, Madoka, Bravver, Elena, Diaz‐Manera, Jordi, Pegoraro, Elena, Mendell, Jerry R., Straub, Volker, Bernatchez, Pascal
• Format: Journal Article
• Language: English
• Published: Germany John Wiley & Sons, Inc 01.08.2025; John Wiley and Sons Inc; Wiley
• Subjects: Adolescent; Adult; Age groups; Asymptomatic; Cholesterol; Cholesterol - blood; Cholesterol, HDL - blood; Clinical outcomes; Cross-Sectional Studies; dysferlin; Dysferlin - deficiency; dyslipidemia; Female; Females; Genotype & phenotype; High density lipoprotein; Homeostasis; Humans; Kinases; Lipids; Lipoproteins; Male; Males; Metabolic disorders; Middle Aged; Muscular Dystrophies, Limb-Girdle - blood; Muscular dystrophy; Original; Patients; Plasma; Serology; Young Adult; Australia; United States > US; Japan; Europe; cholesterol; muscular dystrophy; dyslipidemia; dysferlin
• ISSN: 2190-5991; 2190-6009; 2190-6009
• DOI: 10.1002/jcsm.70042

ABSTRACT Background Limb–girdle muscular dystrophy (MD) type R2 (LGMDR2, formerly LGMD2B) is an autosomal recessive form of MD caused by variants in the dysferlin gene, DYSF. It leads to slow proximal and distal muscle weakening that generally results in loss of ambulation around early adulthood but without the lethal cardiorespiratory dysfunction observed in the more severe Duchenne MD. How loss of dysferlin causes muscle fibre death is poorly understood, but recent evidence suggests a link between muscle wasting and loss of muscle cholesterol homeostasis with circulating lipoprotein abnormalities in many forms of MD. Methods Cross‐sectional circulating total cholesterol (CHOL), high‐density lipoprotein‐associated cholesterol (HDL‐C), non‐HDL‐C, creatine kinase (CK), transaminase levels and bilirubin were collected as part of the Jain Clinical Outcomes Study of Dysferlinopathy, a large multicentre LGMDR2 patient cohort (N = 188), along with ambulatory function values. Results We report that 43%, 49% and 50% of male patients were found to have abnormal circulating CHOL, HDL‐C and non‐HDL‐C levels, respectively, whereas in female patients 39%, 37% and 30% of values were in the abnormal range. Overall, 68% of the total cohort had at least one abnormal cholesterol value (78% of males and 60% of females) and 89% of male CHOL/HDL‐C ratios were in the suboptimal range (above 3.5). Although most patients were ambulant, the severity of circulating lipid abnormalities did not correlate with early loss of ambulation. Transaminase levels were lower in late‐stage LGMDR2 samples, whereas bilirubin remained unchanged, suggesting a low muscular mass rather than hepatic origin and the absence of major liver damage. Conclusions Data from the largest natural history cohort of LGMDR2 patients support the concept that dyslipidemia is a comorbidity of LGMDR2, and the causal role of cholesterol abnormalities in muscle death should be further investigated.